B. McLaughlin Associates, Inc (BMA)

bmaresearch.com

BMA is a niche CRO that has been providing functional support in the areas of Data Management and Study Management for over 20 years. Our unique size, coupled with extensive therapeutic experience, allow us to consistently provide personalized, flexible services, and help clients reach critical clinical trial goals and timelines.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

NAMSA ACQUIRES LEADING CLINICAL RESEARCH ORGANIZATION CLINLOGIX TO ENHANCE THERAPEUTIC EXPERTISE AND GLOBAL FOOTPRINT

NAMSA | August 03, 2021

news image

NAMSA, the world’s only 100% medical device-focused Contract Research Organization (CRO) providing full continuum development solutions, announced today its acquisition of Clinlogix, a leading, Philadelphia-based global clinical research organization. Third in an advancing series, this acquisition follows NAMSA’s purchase announcements of Syntactx and American Preclinical Services (APS) in early 2021. Clinlogix, founded in 1999, is well-recognized for providing compreh...

Read More

Business Insights

TITAN PHARMACEUTICALS ANNOUNCES PRICING OF $5.5 MILLION REGISTERED DIRECT AND PIPE OFFERING PRICED AT-THE-MARKET

Titan Pharmaceuticals, Inc. | February 03, 2022

news image

Titan Pharmaceuticals, Inc. announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 3,374,242 shares of its common stock (or pre-funded warrants in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, Titan has also agreed to issue and sell to the investor 1,289,796 pre-funded warrants, at the same purchase price as in the registered direct offering. In addition, the C...

Read More

Business Insights

ASCLETIS ANNOUNCES SUBMISSION OF MARKETING AUTHORIZATION APPLICATIONS FOR RITONAVIR IN MULTIPLE EUROPEAN COUNTRIES

Ascletis Pharma Inc. | February 14, 2022

news image

Ascletis Pharma Inc.announces that it has submitted marketing authorization applications for ritonavir in Germany, France, Ireland and United Kingdom through its agent in Europe. It is expected that more marketing authorization applications for ritonavir in certain other countries, including the ones in Europe, North America and Asian Pacific will soon be submitted. Ascletis has been in discussion with both domestic and international companies, including major multi-national...

Read More

HOW EHR-INTEGRATED PDMPS INCREASE INTEROPERABILITY, DECREASE BURDEN

EHRIntelligence | March 11, 2020

news image

A prescription drug monitoring program (PDMP) that is implemented into the EHR can decrease the strenuous process of checking the PDMP, thus reducing the cognitive workload and burden for the clinician. However, only one-in-three hospitals can access PDMP data within its EHR system. PDMPs are state-run electronic databases that have been deployed in 49 states, excluding Missouri. The program collects data from pharmacies on Drug Enforcement Agency (DEA) controlled substances and prescription dru...

Read More
news image

Business Insights

NAMSA ACQUIRES LEADING CLINICAL RESEARCH ORGANIZATION CLINLOGIX TO ENHANCE THERAPEUTIC EXPERTISE AND GLOBAL FOOTPRINT

NAMSA | August 03, 2021

NAMSA, the world’s only 100% medical device-focused Contract Research Organization (CRO) providing full continuum development solutions, announced today its acquisition of Clinlogix, a leading, Philadelphia-based global clinical research organization. Third in an advancing series, this acquisition follows NAMSA’s purchase announcements of Syntactx and American Preclinical Services (APS) in early 2021. Clinlogix, founded in 1999, is well-recognized for providing compreh...

Read More
news image

Business Insights

TITAN PHARMACEUTICALS ANNOUNCES PRICING OF $5.5 MILLION REGISTERED DIRECT AND PIPE OFFERING PRICED AT-THE-MARKET

Titan Pharmaceuticals, Inc. | February 03, 2022

Titan Pharmaceuticals, Inc. announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 3,374,242 shares of its common stock (or pre-funded warrants in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, Titan has also agreed to issue and sell to the investor 1,289,796 pre-funded warrants, at the same purchase price as in the registered direct offering. In addition, the C...

Read More
news image

Business Insights

ASCLETIS ANNOUNCES SUBMISSION OF MARKETING AUTHORIZATION APPLICATIONS FOR RITONAVIR IN MULTIPLE EUROPEAN COUNTRIES

Ascletis Pharma Inc. | February 14, 2022

Ascletis Pharma Inc.announces that it has submitted marketing authorization applications for ritonavir in Germany, France, Ireland and United Kingdom through its agent in Europe. It is expected that more marketing authorization applications for ritonavir in certain other countries, including the ones in Europe, North America and Asian Pacific will soon be submitted. Ascletis has been in discussion with both domestic and international companies, including major multi-national...

Read More
news image

HOW EHR-INTEGRATED PDMPS INCREASE INTEROPERABILITY, DECREASE BURDEN

EHRIntelligence | March 11, 2020

A prescription drug monitoring program (PDMP) that is implemented into the EHR can decrease the strenuous process of checking the PDMP, thus reducing the cognitive workload and burden for the clinician. However, only one-in-three hospitals can access PDMP data within its EHR system. PDMPs are state-run electronic databases that have been deployed in 49 states, excluding Missouri. The program collects data from pharmacies on Drug Enforcement Agency (DEA) controlled substances and prescription dru...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us